Calcium Sulfate (sulphate)-Based Nanoparticles: Synthesis and Modification Methods and Application in Bone Regenerative Therapy

University at Buffalo - The State University of New York
posted on 10/20/2009

Bone regeneration within critical size defects, both in the oral cavity and throughout the rest of the body, occurs very slowly in the absence of bone stabilizing agents to act as scaffolds. Though autogenous and allogenic bone grafts have been used to address this limitation, each faces its own set of issues which limit their widespread use. Autogenous bone grafts must be harvested from the patient's donor site, thus requiring a painful and more complex procedure. Allogenic bone grafts serve the same purpose but are plagued by the potential to transmit disease and trigger immune responses, thereby leading to graft rejection. As a result of these shortcomings, the industry has shifted towards synthetic alternatives such as calcium salts (e.g. calcium sulfate), hydroxyapatite, and bioglass. Despite the availability of such alternatives, there remains a need for a product that provides optimal bone regeneration in the most efficient manner possible. In an effort to achieve that end, clinicians have begun adding growth factors to these products, but their size serves as a limiting factor to the amount of growth factors that may be adsorbed. Physician scientists at the University at Buffalo have developed a method for producing unique calcium sulfate nanoparticles (Ncs, Novograft) that act as a superior scaffold for bone regeneration and growth factor adsorption. Unlike the aforementioned alternatives, Novograft is readily available, avoids the risks of infection and rejection, and provides a more robust scaffold for bone growth.

Innovation Details

Detailed Description

Bone regeneration within critical size defects, both in the oral cavity and throughout the rest of the body, occurs very slowly in the absence of bone stabilizing agents to act as scaffolds. Though autogenous and allogenic bonegrafts have been used to address this limitation, each faces its own set of issues which limit their widespread use. Autogenous bone grafts must be harvested from the patient's donor site, thus requiring a painful and morecomplex procedure. Allogenic bone grafts serve the same purpose but are plagued by the potential to transmit disease and trigger immune responses, thereby leading to graft rejection. As a result of these shortcomings, theindustry has shifted towards synthetic alternatives such as calcium salts (e.g. calcium sulfate), hydroxyapatite, and bioglass. Despite the availability of such alternatives, there remains a need for a product that provides optimal bone regeneration in the most efficient manner possible. In an effort to achieve that end, clinicians have begun adding growth factors to these products, but their size serves as a limiting factor to the amount of growth factors that may be adsorbed. Physician scientists at the University at Buffalo have developed a method for producing unique calcium sulfate nanoparticles (Ncs, Novograft) that act as a superior scaffold for bone regeneration and growth factor adsorption. Unlike the aforementioned alternatives, Novograft is readilyavailable, avoids the risks of infection and rejection, and provides a more robust scaffold for bone growth.

File Number: 6122

Disease: Dental

Other Information: Principal Investigator: YoungBum Park

IP Protection

License Online

This innovation currently is not available for online licensing. Please contact Tim Dee at University at Buffalo - The State University of New York for more information.

request more info